Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
|
SE |
|
G
|
Gadoon Textile Mills Ltd
KAR:GADT
|
PK |
|
Abo-Group Environment NV
XBRU:ABO
|
BE |
|
Meratus Jasa Prima Tbk PT
IDX:KARW
|
ID |
|
Astrakhanskaya Energosbytovaya Kompaniya PAO
MOEX:ASSB
|
RU |
|
A
|
Alsons Consolidated Resources Inc
XPHS:ACR
|
PH |
|
G
|
Great Computer Corp
TPEX:8047
|
TW |
|
A
|
Agritech Ltd
KAR:AGL
|
PK |
|
A
|
Advanced Lithium Electrochemistry Cayman Co Ltd
TPEX:5227
|
TW |
|
W
|
Wonder Pets Enterprises Corp
TPEX:6968
|
TW |
|
X
|
Xxtechec Co Ltd
TPEX:8477
|
TW |
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs. Sobi makes money by selling prescription medicines to hospitals, specialty pharmacies, and healthcare systems, often through long-term treatment relationships. Its products include therapies used in hemophilia and other rare blood diseases, as well as medicines for certain immune and inflammatory conditions. The company also works with partners to develop and commercialize some of its treatments, which can add licensing and collaboration income. What makes Sobi different is its focus on a narrow set of rare diseases where patients need highly targeted, specialized care. Instead of selling a broad mix of mass-market drugs, it concentrates on treatments that are used by smaller patient groups but require deep medical expertise, strong relationships with specialists, and reliable supply.
Swedish Orphan Biovitrum, usually called Sobi, is a biopharmaceutical company that develops and sells medicines for rare diseases. Its main focus is on blood disorders, immune-related conditions, and other specialist therapies that treat patients with serious illnesses that are often hard to manage with standard drugs.
Sobi makes money by selling prescription medicines to hospitals, specialty pharmacies, and healthcare systems, often through long-term treatment relationships. Its products include therapies used in hemophilia and other rare blood diseases, as well as medicines for certain immune and inflammatory conditions. The company also works with partners to develop and commercialize some of its treatments, which can add licensing and collaboration income.
What makes Sobi different is its focus on a narrow set of rare diseases where patients need highly targeted, specialized care. Instead of selling a broad mix of mass-market drugs, it concentrates on treatments that are used by smaller patient groups but require deep medical expertise, strong relationships with specialists, and reliable supply.
Strong quarter: Sobi reported revenue of just under SEK 7.8 billion, up 29% at constant exchange rates, and adjusted EBITDA margin of 35%.
Outlook raised: Management increased full-year 2026 guidance for both revenue and adjusted EBITDA margin, citing strong first-half performance and continued momentum.
Launch momentum: Altuvoct, Doptelet, and Gamifant drove growth, while newer launches like Aspaveli continued to build.
Pipeline progress: Sobi highlighted positive REDUCE-2 data for pozdeutinurad, progress in Gamifant sepsis, and additional pipeline milestones expected in 2H 2026 and 2027.
NASP setback: The FDA issued a complete response letter tied to manufacturing and CMC issues, but management said there were no efficacy or safety concerns and that resubmission is planned within 6 to 12 months.